Monday, September 14, 2026

Hanmi Pharmaceutical to Present Phase 2 Clinical Results for Congenital Hyperinsulinism Treatment at European Conference

Hanmi Pharmaceutical will present Phase 2 data on its investigational treatment efpeglenatide (HM15136) for congenital hyperinsulinism at the 64th European Society for Paediatric Endocrinology meeting in France.

3billion Accelerates Global Expansion of AI Genetic Variant Interpretation Platform ZEBRA

3billion is accelerating the global expansion of its ZEBRA AI genetic variant interpretation platform by improving reliability, accessibility and clinical adoption across domestic and international medical and research institutions.

Discover the Legacy: Hanmi Group Unveils Monument Honoring Founder Lim Seong-ki

Hanmi Group honors founder Lim Seong-ki with a bronze sculpture, celebrating his legacy in pharmaceutical innovation and drug development.

Tag: allergies

Korean Doctor Wins Top U.S. ENT Research Award, Paving New Path for Sinusitis Treatment

Kyung Hee University professor Min Jin-young won a prestigious U.S. otolaryngology research award for identifying a new sinusitis mechanism and developing a potential low-cost, personalized treatment strategy.